What are the current guideline recommendations for diagnosing and managing aortic stenosis, including severity criteria, treatment options for symptomatic and asymptomatic patients, and follow‑up?

Recent Guidelines for Aortic Stenosis

All patients with symptomatic severe aortic stenosis require aortic valve replacement (surgical or transcatheter) because medical therapy alone results in approximately 50% mortality within 2–3 years. 1

Diagnostic Criteria for Severe Aortic Stenosis

Severe AS is defined by:

• Aortic valve area (AVA) ≤1.0 cm² (or indexed AVA ≤0.6 cm²/m²) 2
• Peak aortic jet velocity (Vmax) ≥4 m/sec 2
• Mean transvalvular gradient ≥40 mmHg 2

Echocardiography is the primary diagnostic modality and is sufficient for management decisions in 65–70% of patients. 3 When echocardiographic findings are discordant or uncertain (occurring in 25–30% of cases), multimodality imaging with cardiac CT or dobutamine stress echocardiography is recommended. 3

Management of Symptomatic Severe AS

The three cardinal symptoms mandating urgent AVR are:

• Angina 1
• Syncope or near-syncope 1
• Heart failure–related dyspnea 1

Medical management alone is rarely appropriate and should be considered palliative only. 3 Once symptoms develop, average survival without intervention is only 2–3 years, with approximately 25% mortality at 1 year and 50% at 2 years. 4

Risk-Stratified Selection of AVR Modality

The choice between transcatheter AVR (TAVR) and surgical AVR (SAVR) follows a risk-based algorithm:

Prohibitive Surgical Risk

• Definition: ≥50% predicted 30-day mortality or irreversible morbidity, frailty, porcelain aorta, prior chest radiation, severe hepatic or pulmonary disease 1
• Recommendation: TAVR is the treatment of choice 1

High Surgical Risk

• Definition: Society of Thoracic Surgeons (STS) score ≥8% 1
• Recommendation: TAVR is preferred over SAVR 1

Intermediate Surgical Risk

• Definition: STS score 4–8% 3
• Recommendation: Either TAVR or SAVR is acceptable; decision made by multidisciplinary Heart Team considering anatomy, frailty, and patient preference 1, 3

Low Surgical Risk

• Definition: STS score <4% 3
• Recommendation: SAVR is preferred, particularly in patients <65 years for durability, though TAVR is a reasonable alternative in selected cases 3

Management of Asymptomatic Severe AS

Watchful waiting with clinical and echocardiographic surveillance every 6–12 months is appropriate for most asymptomatic patients with normal left ventricular function. 3

Class I Indications for AVR in Asymptomatic Patients

AVR is mandated when:

• Left ventricular ejection fraction (LVEF) <50% (not explained by another cause) 1
• Patient is undergoing other cardiac surgery (e.g., CABG, aortic repair, other valve procedures) 1
• Exercise stress test demonstrates exercise-induced angina, excessive dyspnea early in exercise, dizziness, syncope, limited exercise capacity (below age/sex-specific predicted METs), or abnormal blood pressure response (hypotension or failure to increase BP with exercise) 2, 1

Class IIa Indications for AVR in Asymptomatic Patients

AVR should be strongly considered when:

• Very severe AS with peak velocity ≥5.0 m/sec or mean gradient ≥60 mmHg 1
• Rapid disease progression (increase in jet velocity ≥0.3 m/sec per year with severe valve calcification) 1
• Markedly elevated BNP (>3× age- and sex-adjusted normal) 1

Class IIb Indications

AVR may be considered in:

• High-demand occupations or lifestyles (e.g., commercial pilots, elite athletes) 1
• Patients with LVEF <55% (observational data show higher mortality and benefit from early intervention) 1

Special Diagnostic Scenarios

Low-Flow, Low-Gradient AS with Reduced LVEF

Dobutamine stress echocardiography is essential to distinguish true-severe from pseudo-severe stenosis. 3, 5

Diagnostic approach:

• If contractile reserve is present (stroke volume index increases ≥20%) and AVA remains ≤1.0 cm² with Vmax >4 m/sec, this confirms true-severe AS and AVR is appropriate 2
• If stress testing suggests pseudo-severe stenosis (AVA increases >1.0 cm² with dobutamine), medical management is appropriate 1

Low flow is defined as stroke volume index <35 ml/m². 2

Paradoxical Low-Flow, Low-Gradient AS with Preserved LVEF

Surgery is indicated only when symptoms are clearly present and comprehensive evaluation confirms significant valve obstruction. 1 Multidetector CT for calcium scoring or transesophageal echocardiography can help evaluate morphologic valve alterations. 5

Contraindicated Medical Therapies

The following interventions are explicitly contraindicated (Class III):

• Statins for slowing AS progression (no proven benefit) 1, 3
• Aggressive diuretics in patients awaiting AVR (risk of hemodynamic collapse) 1
• Vasodilators before AVR (potential destabilization) 1
• Positive inotropes in patients awaiting AVR 1

Hemodynamic Management While Awaiting AVR

For patients awaiting valve replacement or non-candidates:

• Maintain adequate preload (avoid excessive diuresis) 3
• Control heart rate to maintain adequate diastolic filling time and avoid tachycardia 3
• Target systolic BP 100–120 mmHg in acute settings 3
• Beta-blockers are the preferred agents for rate control 3

Surveillance Protocol for Asymptomatic Patients

Follow-up echocardiography intervals:

• Every 6 months when risk factors are present (rapid velocity increase, LV hypertrophy) 3
• Every 6–12 months for severe AS 6
• Every 1–2 years for moderate AS 6
• Every 3–5 years for mild AS 6

A rise in aortic jet velocity ≥0.3 m/sec per year signals disease acceleration and should prompt re-evaluation for AVR. 1

Concomitant Conditions

Coronary Artery Disease

For patients with severe AS and significant coronary disease requiring revascularization, combined SAVR + CABG is appropriate. 1 In intermediate/high surgical-risk patients with less complex CAD (low SYNTAX score), catheter-based revascularization may be considered. 1

Mitral Regurgitation

• Primary mitral regurgitation does not improve after isolated AS correction; a concomitant or staged mitral procedure is required. 1
• Secondary mitral regurgitation may improve after isolated AVR, depending on LV dysfunction and leaflet tethering. 1

Tricuspid Regurgitation

Severe tricuspid regurgitation should be treated whenever feasible because it portends poor prognosis. 1

Bicuspid Aortic Valve with Ascending Aortic Aneurysm

When the ascending aorta measures ≥4.5 cm, simultaneous surgical repair of the valve and aorta should be considered. 1 Initial evaluation should include aortic root and ascending aorta dimensions, as 50% of bicuspid valve patients have aortic root involvement. 4 If ascending aorta diameter exceeds 4.0 cm, yearly imaging surveillance is required. 4

Non-Cardiac Surgery Considerations

For symptomatic severe AS requiring major non-cardiac surgery:

• Proceeding without addressing the valve is rarely appropriate due to markedly increased perioperative morbidity and mortality (approximately 10% mortality risk) 1, 4
• Performing SAVR or TAVR before the non-cardiac operation is appropriate 1
• Balloon aortic valvuloplasty may be used as a temporizing bridge to definitive AVR 1

For asymptomatic severe AS undergoing elective major surgery:

• A conservative (no-intervention) approach may be reasonable, although AVR (TAVR or SAVR) is also acceptable 1

For urgent non-cardiac surgery:

• Proceed with careful hemodynamic monitoring 3

Balloon Aortic Valvuloplasty

Balloon valvuloplasty is a Class IIb (limited) option reserved for:

• Palliative relief in patients unsuitable for AVR due to severe comorbidities 1
• Bridge to definitive surgical AVR 1

It provides only temporary modest improvement with high complication rates (>10%) and restenosis within 6–12 months. 4

Heart Team Approach

All complex decisions require a multidisciplinary Heart Team comprising:

• Cardiac surgery 2
• Interventional cardiology 2
• Cardiac imaging 2
• Anesthesiology 2
• Geriatrics (when appropriate) 2

The Heart Team must:

• Evaluate individual patient risk, technical/anatomic suitability 1
• Assess frailty and comorbidities not captured by conventional risk scores 1
• Align treatment with patient goals and life expectancy 3

Particularly complex transcatheter or surgical procedures, or procedures performed on asymptomatic patients, should be done at centers with appropriate expertise to minimize complications. 2

Critical Pitfalls to Avoid

• Delaying AVR after symptom onset markedly reduces survival; prompt intervention is essential 1
• Missing a reduced LVEF (<50%) in an asymptomatic patient constitutes a missed Class I indication for AVR 1
• Prescribing statins with the expectation of slowing AS progression is ineffective 1
• Exercise testing can unmask subtle symptoms in patients who consider themselves asymptomatic and should be performed when uncertainty exists 2, 1
• Distinguishing normal exercise limitations from abnormal symptoms due to AS requires careful assessment of exercise-induced angina, excessive dyspnea early in exercise, dizziness, syncope, limited exercise capacity, or abnormal BP response 2